Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Fabio Conforti

Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy

Federico Merlo

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy

Laura Pala

Humanitas University, Milan, Italy

Jacopo Canzian

Humanitas University, Milan, Italy

Benedetta Tinterri

Humanitas University, Milan, Italy

Tommaso De Pas

Humanitas University, Milan, Italy

Marzia Locatelli

Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy

James C. Dickerson

James C. Dickerson, MD, MS, Jennifer L. Caswell-Jin, MD, and Fauzia Riaz, MD, MHS, Department of Medicine (Hematology and Oncology), Stanford University, Stanford, CA; and Jeremy D. Goldhaber-Fiebert, PhD, and Fernando Alarid-Escudero, PhD, Department of Health Policy, Stanford University, Stanford, CA

Javier Cortés

International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona

Dennis J. Slamon

Richard Gelber

Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA

Vincenzo Bagnardi

Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy